Cosmos Interest Expense from 2010 to 2026
| COSM Stock | | | USD 0.37 0.01 2.01% |
Long-term reporting places Interest Expense within a compressing cycle. Interest Expense is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.
View All Fundamentals Interest Expense | First Reported 2009-09-30 | Previous Quarter 551.9 K | Current Value 669.1 K | Quarterly Volatility 548.6 K |
Macro event markers
Credit Downgrade | Yuan Drop | Covid | Interest Hikes |
Compare Cosmos Health against competitors using
Cosmos Health Correlation. This adds peer-relative context.
To understand the process of investing in Cosmos Stock, visit our
How to Invest in Cosmos Health guide.
Evaluating Cosmos Health's Interest Expense across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cosmos Health's fundamental strength.
Latest Cosmos Health's Interest Expense Growth Pattern
Below is the plot of the Interest Expense of Cosmos Health over the last few years. It is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. Cosmos Health's Interest Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cosmos Health's overall financial position and show how it may be relating to other accounts over time.
| Interest Expense | 10 Years Trend | | |
Cosmos Interest Expense Regression Statistics
| Arithmetic Mean | 1,500,640 |
| Geometric Mean | 250,271 |
| Coefficient Of Variation | 124.38 |
| Mean Deviation | 1,362,484 |
| Median | 1,012,314 |
| Standard Deviation | 1,866,561 |
| Sample Variance | 3.5T |
| Range | 6.8M |
| R-Value | 0.41 |
| Mean Square Error | 3.1T |
| R-Squared | 0.17 |
| Significance | 0.1 |
| Slope | 152,737 |
| Total Sum of Squares | 55.7T |
Cosmos Interest Expense History
| 2026 | 1.6 M | |
| 2025 | 1.2 M | |
| 2024 | 1 M | |
| 2023 | 866.5 K | |
| 2022 | 4 M | |
| 2021 | 3.6 M | |
| 2020 | 2.8 M | |
About Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. Cosmos Holdings Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 95 people. Liquidity and trading activity can influence how quickly new information is reflected in Cosmos Health's price. Lower liquidity may increase execution variability. Cosmos Health has a market cap of 16.65 M, P/E of 2.41, ROE of -63.82%.
Methodology
Unless otherwise specified, financial data for Cosmos Health is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cosmos (USA Stocks:COSM) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA) as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Cosmos Health may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try Portfolio ProphetMore Resources for Cosmos Stock Analysis
Reviewing Cosmos Health commonly begins with
financial statements and performance trends. Ratios and trend metrics help frame Cosmos Health's operating context.
Outlined below are key reports that provide context for Cosmos Health Stock: Compare Cosmos Health against competitors using
Cosmos Health Correlation. This adds peer-relative context.
To understand the process of investing in Cosmos Stock, visit our
How to Invest in Cosmos Health guide.
Analysis related to Cosmos Health should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the
Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Earnings Share -0.77 | Revenue Per Share | Quarterly Revenue Growth 0.379 | Return On Assets | Return On Equity |
Investors evaluate Cosmos Health using market value and book value, each describing different facets of the business. Cosmos Health's market capitalization is 16.65 M. A P/B ratio of 0.58 suggests Cosmos Health trades near or below book value. Enterprise value stands at 33.68 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Cosmos Health are related but not identical, and they can diverge across cycles. For Cosmos Health, key inputs include a P/E ratio of 2.41, a P/B ratio of 0.58, a profit margin of -31.01%, and ROE of -63.82%. Market price reflects the current exchange level formed by active bids and offers.
Rifka Kats ยท Member of Macroaxis Editorial Board